Skip Navigation
 
MUSC 
 
About FRD
    For Inventorsfor IndustryFor Entrprenuers
Online Licensing
Available Technologies

Information and Resources

Agreements

Frequently Asked Questions

  
 Start-Up Resources 
 SBIR/STTR Programs 
     
  • Targeting CD26hi T-cells for Cancer Therapy
     
    Inventors at MUSC have identified a unique human CD4+ T cell population that expresses high levels of surface CD26, termed CD26high T cells, which mediate durable antitumor immunity in vivo, and have immediate clinical relevance for designing new vaccines and cellular therapies.

     CD26high T cells simultaneously secrete elevated IL-17A, IFN-? and IL-22 compared to Th1, Th2 or Th17 cells. When infused into mice bearing human tumors, CD26high T cells more efficiently reconstituted immunodeficient hosts and persisted long-term compared to other subsets. Remarkably, CD26high T cells engineered with a first generation CD3? mesothelin-specific chimeric antigen receptor (CAR) were capable of ablating large human mesothelioma tumors when infused into mice. 

    Read more...

     
  • Spinal Implant System for Reduction & Internal Implant Stabilization of Human Spondylolisthesis Deformity
     
    The Hercules spinal implant device and system is to be used for reduction and internal implant stabilization of human vertebral spondylolisthesis deformity. It is a standalone system with unique design that allows an anterior surgical approach to realign and simultaneously stabilize the spinal vertebral segments while protecting and preserve nerve function and not damaging other human body visceral anatomy in order to correct all grades of spondylolisthesis. The proposed solution is to use two implants in the interbody space, allowing greater flexibility to handle high grades of spondylolisthesis that utilize a locking mechanism when the spine has returned to proper alignment to provide the same stability as that of a single implant. Additionally, the reduction system used to realign the spine is designed to minimize the physical strain of the surgeon while realigning the spine, which could have high resistive forces in high grades of spondylolisthesis.  This spinal reduction system is able to treat any grade of spondylolisthesis without supplemental fixation. This is used to treat patients with the spondylolisthesis deformity that causes extreme back or leg pain, and who have found no improvement with more conservative treatment options.
  • Titanium Clip Metal Detector to Aid Breast Surgery
     
    This titanium metal detector localizes titanium biopsy clips placed at the site of breast tissue biopsies. The device is a handheld metal detector that can be inserted into a surgical incision to help locate small titanium markers without an invasive procedure to insert a localizing wire or radioactive seed. The device uses a two-step detection system which is initiated by running the scanning wand across the patient’s breast as a means of rapidly guiding clinicians to the marker’s general location. Once an approximate location is determined, the probing wand is used to identify the marker’s precise location. An incision is made and the probing wand guides the surgeon’s path to the marker through continuous feedback. The system relates proximity information to clinicians both through auditory feedback mechanisms and a digital display on the base.
  • Cooperative Therapeutic Effect of Immune Checkpoint Blockade & Anti-sMIC
     
    The invention is a new immune-based therapy modality to treat MIC+ malignancies by the combination of a sMIC neutralizing antibody and an immune checkpoint agonist. This invention presents that a combination of sMIC antibody and anti-CTLA4 or anti-PD1/PD-L1 has superior therapeutic effect over monotherapy of individual reagents. This is a new therapeutic modality to improve the clinic response to anti-CTLA4 or anti-PD1/PD-L1 therapy.  
  • Special Imagine 20/20 Event: MUSC Chapter National Academy of Inventors
     
    Dr. Kathleen Brady and the MUSC Foundation for Research Development invite you to attend the Induction and Recognition of Members of the MUSC Chapter of the National Academy of Inventors.

    Wednesday, January 18, 2017 - 4:00pm to 6:00pm
    Lobby of Drug Discovery Building
    James E. Clyburn Research Center
    70 President St.
    Charleston, SC 29425

    RSVP: Harriette Bayse, Executive Assistant, bayse@musc.edu
  • SCTR/FRD Technology Development Grants Now Open
    Funding: $25k/6 months

    The primary objective of these awards is to support projects that have a high chance of being commercialized, but that are not likely to get there without gap funding. Funds are intended to advance projects to the next developmental milestone by enabling investigators to conduct additional experiments, such as those that:
    • Optimize compounds, conduct toxicology studies, or help define a pharmacological target or translational biomarker
    • Prototype a device
    • Build or validate a software program
    This RFA is open to advance technologies protected by, or protectable by, IP that is assigned or assignable to MUSC pursuant the MUSC IP Policy. If a patent or patent application is not currently assigned to FRD, a Record of Invention must be on file with FRD at least one month in advance of the Pre-Application open date.

    Pre-Application Due Date: January 17, 2017
    Contact: Ford Simmons, MLIS - simmonwi@musc.edu
  • Neuroene Therapeutics Awarded $225,000 STTR Research Grant

    Startup rooted in MUSC investigators’ efforts to find new anti-seizure drugs

    Charleston, S.C. (Aug. 24, 2016) – Neuroene Therapeutics, a startup company born from unique research by two Medical University of South Carolina (MUSC) investigators, secured a Small Business Technology Transfer (STTR) grant for $225,000 in July from the National Institute of Neurological Disorders and Stroke (NINDS).

    Neuroene Therapeutics is using the Phase I STTR grant to help further develop a novel class of compounds for treating epilepsy. In the U.S. alone, epilepsy’s estimated direct and indirect costs total $15.5 billion, according to the Health and Medicine Division of the National Academies of Sciences.

    Read More
     
  • SCTR Technology Development Grant Awardees
     
    Congratulations to Nathan Dolloff, Ph.D. and James Chou, Ph.D. on receiving the most recent SCTR technology development grants.

    James Chou, Ph.D.'s research focus is centered around the neuro-vitamin K (VK) synthase UBIAD1, which has recently been identified through a forward genetic screen as a dominant enhancer of the Parkinson’s disease (PD) establishing an additional link among mitochondria, vitamin K, and PD pathogenesis. Supplementation of VK reverses the non-flight phenotype observed in the drosophila model.  Unfortunately, for humans, neuronal VK requires a series of metabolic processes and direct synthesis by UBIAD1 in the central nervous system in situ, and cannot be supplemented through dietary means.  We have developed VK analogs that can easily penetrate blood-brain barrier and showed effective in the chemical induced PD model.  The SCTR-FRD Grant will allow the optimization of the lead drug candidate’s dosing routine instead of performing the costly efficacy experiments blindly.  With the funded study, it will also significantly move the project forward for future efficacy studies.

    Click here to continue.
  • MUSC, Harbor Entrepreneur Center to launch life-science tech accelerator in Charleston

    Charleston’s growing medical technology industry will be the focus of a new accelerator program launching this fall.

    The program, called PriMed, aims to give a boost to startups that make products like medicines and medical devices when it takes in its first group of companies in September.

    The initiative is a collaboration between the Harbor Entrepreneur Center, which runs an accelerator for traditional tech startups, and the Medical University of South Carolina’s Foundation for Research Development, which helps make the school’s inventions commercially available.

    Read more here.
  • FRD Welcomes Two New Board Members
     
    The MUSC Foundation for Research Development (FRD) welcomes two new board members. These two new members exemplify innovation and development and will be a great asset to the Foundation. Welcome!
     
    Dr. Robert D. McQuade
    Ph.D. | Biochemistry, UNC
    Currently Executive Vice President and Chief Strategic Officer at Otsuka Pharmaceuticals Development and Commercialization.

    Dr. Paul Williamson
    M.D | University of Massachusetts



     
  • MUSC Start-Up Wins Prestigious National Award
     
    Congratulations to ToleRaM Nanotech, LLC  for winning a National TechConnect Innovation Award, which is meant to recognize innovative technology that has the potential to make a difference in a special sector, such as medicine. Only 15% of submitted entries receive the prestigious award.
     
    Click here for more information.
View All TechnologiesFollow Us on Facebook
Follow Us on TwitterFollow Us on LinkedIn!
MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Harborview Office Tower, 19 Hagood Avenue, Suite 909, Charleston, SC 29403    Ph. 843.876.1900  Fx. 843.876.1905
© 2015 MUSC Foundation for Research Development